Loan & DebtApr 16, 2026, 04:07 PM
Emergent BioSolutions Secures New $150M Term Loan, Extends Maturities
AI Summary
Emergent BioSolutions Inc. announced the closing of a new $150 million term loan agreement with OrbiMed, using the proceeds to repay its previous term loan facility. The company also amended its $50 million asset-based revolving loan facility (ABL) with Wells Fargo. Both agreements extend maturities to April 2031, providing five years of financial flexibility. Management expects these actions to reduce interest expense by 200 basis points annually and bolster cash position, supporting its multi-year transformation plan.
Key Highlights
- Closed new $150 million term loan with OrbiMed.
- Repaid previous term loan facility with Oak Hill Advisors.
- Amended $50 million asset-based revolving loan facility (ABL).
- Extended maturities for both facilities to April 2031 (five years).
- Reduced interest expense on new term loan by 200 basis points annually.